The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, phase Ib dose-expansion study to assess the efficacy of CD137/FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive head and neck squamous cell carcinoma (HNSCC).
 
Rachna Shroff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; Jazz Pharmaceuticals; Merck; Merus
Research Funding - Actuate Therapeutics; Bristol-Myers Squibb; Compass Therapeutics; Exelixis; Faeth Therapeutics; Fujifilm; Immunovaccine; Lisata; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; Rafael Pharmaceuticals; Seagen
 
Dejan Radonjic
Employment - Boehringer Ingelheim
 
Jianrui Hou
Employment - Boehringer Ingelheim
 
Marta Puig
Employment - Boehringer Ingelheim
 
Jean-Pascal Machiels
Consulting or Advisory Role - ALX Oncology; ANAVEON (Inst); Astellas Pharma (Inst); AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CUE Biopharma; CureVac (Inst); eTHERNA; F-star; Genmab (Inst); GlaxoSmithKline (Inst); Incyte; Innate Pharma; IPSEN (Inst); ITeos Therapeutics; Janssen; Merck Serono; Merus (Inst); MSD Oncology (Inst); NEKTAR; Novartis; Pfizer; Roche; Seagen (Inst); Seagen (Inst)
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Gilead Sciences; Merck Serono (Inst); MSD; Pfizer
Other Relationship - PsiOxus Therapeutics